<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793662</url>
  </required_header>
  <id_info>
    <org_study_id>NLAST2012</org_study_id>
    <nct_id>NCT01793662</nct_id>
  </id_info>
  <brief_title>Norwegian Laparoscopic Aortic Surgery Trial</brief_title>
  <acronym>NLAST</acronym>
  <official_title>Norwegian Laparoscopic Aortic Surgery Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe atherosclerotic occlusive disease can be operated with an aortobifemoral&#xD;
      bypass(ABFB)through a median laparotomy. Since 1993, the vary operation has also been&#xD;
      performed laparoscopically. The laparoscopic ABFB operation claims to be minimally invasive&#xD;
      as compared to the open ABFB. The cohort studies published so far have shown that although a&#xD;
      longer operation time with the laparoscopic procedure as compared to the open surgery, the&#xD;
      patients have a shorter hospital stay, lesser perioperative bleeding, fewer systemic&#xD;
      complications and earlier reconvalescence.&#xD;
&#xD;
      However, no randomized control trial has yet been published to compare the two procedures.&#xD;
&#xD;
      In the NLAST-study, which is a multicenter randomized control trial, the patients with TASC&#xD;
      type D atherosclerotic lesion shall be randomized to either totally laparoscopic&#xD;
      aortobifemoral bypass operation (LABFB)or an open ABFB operation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary end point of the study is post-operative complications defined as systemic and&#xD;
      local complications, including the vascular complications e.g., graft infection, thrombosis&#xD;
      etc.&#xD;
&#xD;
      Secondary end points are as follows,&#xD;
&#xD;
        -  health related quality of life examined and evaluated with the help of pre and&#xD;
           post-operative survey performed with the help of SF36v2 questionnaire and EQ5D5L.&#xD;
&#xD;
        -  peri operative stress response (during operation) measured/ analysed with the help of&#xD;
           stress hormones changes&#xD;
&#xD;
        -  periopersative inflammatory response&#xD;
&#xD;
        -  cost utility analysis&#xD;
&#xD;
        -  cost differences&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>Post operative complications(early- within 30 days) shall be registered and analyzed in the two groups of patients. However, late complications shall also be registered although not defined as the primary end-point of the NLAST study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>health related quality of life</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>The bodily pain domain of the SF36-v2 at 3 months postoperatively shall be used to assess the patients in the two groups of NLAST study. Besides EQ-5D-5L shall be used pre and post operatively for QoL evaluation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Operative stress response</measure>
    <time_frame>During operation</time_frame>
    <description>During operation changes in the stress hormones e.g., adrenalin, cortisol etc shall be analyzed in the two patients groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost utility examination</measure>
    <time_frame>30 days</time_frame>
    <description>In hospital cost of the treatment shall be calculated. Cost utility examination shall be performed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory stress response</measure>
    <time_frame>30 days</time_frame>
    <description>Changes in the pro-inflammatory interleukins etc shall be registered during and after operation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Aortobifemoral Bypass</condition>
  <condition>Aortoiliac Occlusive Disease</condition>
  <condition>TASC Type D Lesions</condition>
  <condition>Laparoscopic Versus Open Bifurcation Graft</condition>
  <arm_group>
    <arm_group_label>Open aortobifemoral bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laparoscopic aortobifemoral bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic aortobifemoral bypass</intervention_name>
    <description>Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.</description>
    <arm_group_label>Laparoscopic aortobifemoral bypass</arm_group_label>
    <arm_group_label>Open aortobifemoral bypass</arm_group_label>
    <other_name>Laparoscopic aortic surgery</other_name>
    <other_name>laparoscope</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aortoiliac occlusive disease (TASC Type D lesions)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active cancer disease&#xD;
&#xD;
          -  Acute critical limb ischemia&#xD;
&#xD;
          -  Prior major abdominal surgery&#xD;
&#xD;
          -  Heart failure (Ejection fraction &lt;40%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syed Sajid Hussain Kazmi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of vascular surgery, Oslo University Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Syed Sajid H Kazmi, MD, PhD</last_name>
    <phone>004792468309</phone>
    <email>sshkazmi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jørgen J Jørgensen, MD, PhD</last_name>
    <phone>004795286086</phone>
    <email>j.j.jorgensen@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of vascular surgery, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Sajid Hussain Kazmi, MD, PhD</last_name>
      <phone>004792468309</phone>
      <email>sshkazmi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Syed Sajid Hussain Kazmi</investigator_full_name>
    <investigator_title>Consultant Surgeon</investigator_title>
  </responsible_party>
  <keyword>Aortobifemoral bypass</keyword>
  <keyword>Laparoscopic aortic surgery</keyword>
  <keyword>Aortoiliac occlusive disease</keyword>
  <keyword>TASC Type D Lesions</keyword>
  <keyword>Open aortic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leriche Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

